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Lung function declines more rapidly in treated HIV-positive 
people than in HIV-negative people 
As ever greater numbers of people living with HIV 
now have access to antiretroviral therapy and achieve 
sustained viral suppression,1 the focus of HIV care 
turns toward optimising long-term outcomes of 
age-associated non-communicable comorbidities 
that are common in people living with HIV, including 
obstructive pulmonary disease.2 Cohort and cross-
sectional studies demonstrate higher prevalence 
of respiratory symptoms, diagnoses (eg, COPD or 
emphysema), abnormal lung imaging (eg, emphysema), 
and impairments on spirometry and diffusion capacity 
measurements in people living with HIV.3 Though 
increased smoking among people living with HIV 
is a contributor,4 associations between HIV and 
impairments in pulmonary function are independent 
of smoking. Legacy effects of uncontrolled HIV 
infection before initiation of antiretroviral therapy (eg, 
bacterial pneumonia, tuberculosis, Pneumocystis jirovecii 
pneumonia, immunosuppression, and viral replication), 
and ongoing chronic inflammation despite viral 
suppression are also implicated.5 As the prevalence of 
pulmonary morbidity is increased in older people living 
with HIV, an epidemic of chronic lung disease in people 
living with HIV could emerge as cohorts age. 
However, cross-sectional studies have limitations and 
prospective longitudinal studies with appropriate HIV-
negative controls that also control for confounding 
risk behaviours (eg, smoking) are needed to discern the 
relative contribution of HIV infection and risk behaviour 
to ongoing lung damage and to predict the trajectory of 
these lung diseases with ageing. 
In The Lancet Healthy Longevity, Sebastiaan Verboeket 
and colleagues6 report results from the prospective 
AGEhIV cohort study. Over a median follow-up of 
6 years, the investigators regularly measured pre-
bronchodilator spirometry in 500 virally suppressed 
people living with HIV and, crucially, compared them 
with a demographically and lifestyle-matched control 
group of 481 HIV-negative individuals recruited from a 
sexual health service in the Netherlands. 
Forced expiratory volume in 1 s (FEV1) declined over 
time in all participants, and declines in FEV1 and the 
ratio of FEV1 to forced vital capacity (FVC) were steeper 
for current smokers than non-smokers, for both HIV-
positive and HIV-negative participants. However, 
although both smoking and non-smoking HIV-
negative control participants showed relatively little 
change in FVC and a rate of FEV1 decline similar to that 
seen in healthy population studies,7 smoking and non-
smoking HIV-positive participants had significantly 
steeper declines in FEV1 and FVC. These associations 
with HIV remained when analyses were restricted 
to the quintile with the highest declines. Notably, 
however, FEV1/FVC ratio decline was not greater in HIV-
positive participants, a pattern that suggests declines 
related to HIV infection are phenotypically distinct 
from declines related to smoking and that will require 
more sophisticated measures of pulmonary function 
to dissect the contribution of small airways and 
parenchymal damage.8,9 
The association of faster FEV1 and FVC decline with 
HIV remained statistically significant in both current 
smokers and non-smokers (ie, former smokers or those 
who never smoked]), but when analyses were restricted 
to only those participants who had never smoked, this 
trend was no longer statistically significant. Importantly, 
the HIV-positive group included more current or former 
smokers, with greater smoking pack-years, compared 
with the HIV-negative group. However, the absolute 
differences in smoking prevalence between the HIV-
positive and HIV-negative groups were small, and the 
effect of smoking pack-years on the association between 
HIV status and declines in FEV1 and FVC was not significant 
in sensitivity analyses. Importantly, neither nadir CD4 
count, previous P jirovecii pneumonia, nor previous 
pulmonary tuberculosis were associated with faster FEV1 
or FVC decline in HIV-positive participants, suggesting 
that ongoing effects of HIV-related pulmonary damage, 
rather than HIV-associated legacy effects, underlie these 
declines.
The team also sought to measure markers of HIV-
associated inflammation. Elevated baseline and time-
updated concentrations of high-sensitivity C-reactive 
protein were associated with faster FEV1 and FVC decline 
in the HIV-positive group but not in the HIV-negative 
group. Again, this association was not statistically 
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significant in participants who never smoked, and it 
is therefore not possible to rule out the possibility that 
the observed association between high-sensitivity 
C-reactive protein and lung function decline was driven 
by smoking. HIV-specific associations between lung 
function change and other inflammatory markers 
were less consistent. Nevertheless, these issues do not 
exclude an important role of chronic inflammation but 
rather, as the investigators suggest, point to the need 
for measurements directly from the lung compartment. 
This has been achieved in cross-sectional studies, most 
recently with the demonstration that airway basal 
stem (progenitor) cells isolated from virally suppressed 
HIV-positive but not HIV-negative non-smokers 
spontaneously release inflammatory mediators.10
Thus, the study demonstrated that HIV is associated 
with faster lung function decline independent of 
smoking or legacy effects from before initiation of 
antiretroviral therapy, and further supports a role of 
chronic immune activation in this association. The 
phenotypic difference between declines in HIV-related 
pulmonary function and declines related to smoking 
provide further support that the evidenced effects on 
pulmonary health were driven largely by HIV status. 
The key message, then, is that as the trajectory of lung 
function decline is steeper in people living with HIV 
as they age, a larger proportion of people living with 
HIV than might be expected will cross the threshold 
of symptomatic disease. The implications are that 
health services for people living with HIV will need to 
be prepared to diagnose and manage patients with 
symptomatic airways disease and to learn to predict and 
intervene for those who are at risk. 
Several questions still need addressing. First, there 
were few non-white and female participants in the 
study, and these individuals also completed fewer 
follow-up visits. Do women and those of non-white 
ethnicity also have accelerated lung function decline? 
Given that COPD is more common in people living with 
HIV compared with HIV-negative people in every WHO 
region, do the study findings generalise to low-income 
and middle income countries?11 Second, as the study did 
not correlate symptoms with lung function, the extent 
and timing of the clinical effect of this decline remains 
uncertain. Third, as cost-effective strategies for early 
detection and treatment of COPD are challenging,12 
what profile of risk factors, biomarkers, and lung 
function and imaging tests should be employed? Finally, 
does a phenotypically distinct pattern of disease driven 
by chronic inflammation require novel interventions 
and will current treatment approaches for obstructive 
airways diseases be effective in people living with HIV? 
We now have the evidence that lung function declines 
more rapidly in HIV-positive people. What then, other 
than support for smoking cessation, needs to be done?
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